EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

By P. R. R. Ecurrent, E. Rial. 2001

3,149 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/22542c6d9c567d62c63e70ca7a3c206eedcc3951

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel (2009, background): “1% absolute risk reduction conferred by clopidogrel in the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) study.(1) Our findings have major implications for public health, given the number of patients exposed to this drug interaction.”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “dogrel to aspirin in both non-diabetic and diabetic patients with acute coronary syndrome.(145) In TRITON-TIMI 38 trial, patients with acute coronary syndromes undergoing percutaneous revascularization”
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. (2005, neutral): “(%) NA 36 (18) 240 (26) 299 (12) 613 (28) 33 (25) 244 (13) 1465/7735 (18.”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, positive): “Following an episode of ACS, dual antiplatelet therapy given for a period of 12 months is a standard treatment based on results from the CURE [455], TRITON [456] and PLATO [457] studies, whereas no clinical studies support the use of prasugrel and ticagrelor in patients with stable CAD.”
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. (2002, background): “Clopidogrel, has been investigated in aspirin (75– 325 mg) treated ACS patients in a large clinical trial (CURE) of 12 562 patients([153]).”
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2016, methodology): “0% absolute increase inmajor bleeding.(52) Themajority of patients in this study were treated without revascularization, though benefit was observed both in those treated with revascularization (PCI or CABG) and in those treated with medical therapy alone.”